Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Angeles Clinic and Research Institute

SYNERGY: nenocorilant and nivolumab in advanced solid malignancies
1:38
SYNERGY: nenocorilant and nivolumab in advanced solid malignancies
Omid Hamid • 31 May 2026
Prior CTLA-4 blockade linked to immunosuppressive signature in melanoma
2:05
Prior CTLA-4 blockade linked to immunosuppressive signature in melanoma
Omid Hamid • 31 May 2026
Novel treatments for advanced melanoma patients who have failed initial therapy
3:04
Novel treatments for advanced melanoma patients who have failed initial therapy
Omid Hamid • 21 Jul 2025
DANTE: evaluating 1 vs 2 years of anti-PD-1 therapy in metastatic melanoma
1:39
DANTE: evaluating 1 vs 2 years of anti-PD-1 therapy in metastatic melanoma
Omid Hamid • 3 Jun 2025
Triplet therapy improves PFS in melanoma brain metastases in SWOG S2000
1:15
Triplet therapy improves PFS in melanoma brain metastases in SWOG S2000
Omid Hamid • 3 Jun 2025
DREAMseq: 5-year follow up of first-line dual IO in BRAFV600-m melanoma
1:47
DREAMseq: 5-year follow up of first-line dual IO in BRAFV600-m melanoma
Omid Hamid • 3 Jun 2025
Key melanoma highlights from ASCO 2024, including RELATIVITY-048 and NADINA trials
4:14
Key melanoma highlights from ASCO 2024, including RELATIVITY-048 and NADINA trials
Omid Hamid • 8 Aug 2024
IMC-F106C, a novel PRAME × CD3 ImmTAC, in metastatic cutaneous melanoma
6:25
IMC-F106C, a novel PRAME × CD3 ImmTAC, in metastatic cutaneous melanoma
Omid Hamid • 7 Jun 2024
The benefits of tebentafusp in uveal melanoma
1:55
The benefits of tebentafusp in uveal melanoma
Omid Hamid • 10 Nov 2023
Elucidating biomarkers of response in the RELATIVITY-047 trial
2:01
Elucidating biomarkers of response in the RELATIVITY-047 trial
Omid Hamid • 10 Nov 2023
C-144-01: lifileucel in mucosal melanoma pretreated with ICIs
1:54
C-144-01: lifileucel in mucosal melanoma pretreated with ICIs
Omid Hamid • 10 Nov 2023
The future of BiTEs and ImmTACs in melanoma and beyond
2:31
The future of BiTEs and ImmTACs in melanoma and beyond
Omid Hamid • 10 Nov 2023
Immunotherapy at ASCO 2023: updates in neoadjuvant and adjuvant therapy
1:23
Immunotherapy at ASCO 2023: updates in neoadjuvant and adjuvant therapy
Omid Hamid • 8 Jun 2023
Combining GITR inhibitors with immunotherapy in advanced cancers
0:34
Combining GITR inhibitors with immunotherapy in advanced cancers
Omid Hamid • 7 Jun 2023
Triple PD-1, LAG-3 and TIM-3 inhibition in solid tumors
1:28
Triple PD-1, LAG-3 and TIM-3 inhibition in solid tumors
Omid Hamid • 7 Jun 2023
Post adjuvant PD-1 analysis of fianlimab and cemiplimab in melanoma
3:26
Post adjuvant PD-1 analysis of fianlimab and cemiplimab in melanoma
Omid Hamid • 7 Jun 2023
The content of VJOncology is intended for healthcare professionals